Statement of Ownership (sc 13g)
December 22 2017 - 12:42PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
13G
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT
NO. ___)
AKERS
BIOSCIENCES, INC.
(Name
of Issuer)
COMMON
STOCK, PAR VALUE $0.001
(Title
of Class of Securities)
00973E102
(CUSIP
Number)
December
21, 2017
(DATE
OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c)
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter the
disclosures
provided in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
(Continued
on following page(s))
Page
1 of 5 Pages
CUSIP
No. 00973E102
|
|
13G
|
|
Page
2 of 5 Pages
|
1.
|
NAME
OF REPORTING PERSONS
S.S.
OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Alpha
Capital Anstalt
|
2.
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) ☐
(b) ☐
|
3.
|
SEC
USE ONLY
|
4.
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Liechtenstein
|
NUMBER
OF SHARES BENEFICIALLY OWNED BY
EACH
REPORTING PERSON
|
5.
|
SOLE VOTING POWER
2,516,635 shares of Common Stock (1)
|
6.
|
SHARED VOTING POWER
None
|
7.
|
SOLE DISPOSITIVE POWER
2,516,635 shares of Common Stock (1)
|
8.
|
SHARED DISPOSITIVE POWER
None
|
9.
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,516,635
shares of Common Stock (1)
|
10.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☒
The
aggregate amount in Row 9 represents the maximum amount of shares that Alpha Capital Anstalt (“Alpha”) can beneficially
control under a contractually stipulated 9.9% ownership restriction. The full conversion and/or exercise of Alpha’s securities
would exceed this restriction.
|
11.
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.9%
|
12.
|
TYPE
OF REPORTING PERSON
CO
|
(1)
Based on 25,420,551 shares outstanding as of December 21, 2017
CUSIP
No. 00973E102
|
|
13G
|
|
Page
3 of 5 Pages
|
ITEM
1 (a) NAME OF ISSUER: Akers Biosciences, Inc.
ITEM
1 (b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
201
Grove Road, Thorofare, NJ 08086
ITEM
2 (a) NAME OF PERSON FILING: Alpha Capital Anstalt
ITEM
2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Lettstrasse
32, FL-9490 Vaduz, Furstentums, Liechtenstein
ITEM
2 (c) CITIZENSHIP: Liechtenstein
ITEM
2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, par value $0.001
ITEM
2 (e) CUSIP NUMBER: 00973E102
ITEM
3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable
ITEM
4 OWNERSHIP
(a)
AMOUNT BENEFICIALLY OWNED: 2,516,635 shares of Common Stock (1)
(b)
PERCENT OF CLASS: 9.9%
(c)
NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i)
SOLE POWER TO VOTE OR DIRECT THE VOTE
2,516,635
shares of Common Stock (1)
(ii)
SHARED POWER TO VOTE OR DIRECT THE VOTE
0
Shares
(iii)
SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
2,516,635
shares of Common Stock (1)
(iv)
SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
0
Shares
CUSIP
No. 00973E102
|
|
13G
|
|
Page
4 of 5 Pages
|
ITEM
5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not
applicable
ITEM
6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not
applicable
ITEM
7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY
Not
applicable
ITEM
8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP
Not
applicable
ITEM
9 NOTICE OF DISSOLUTION OF GROUP
Not
applicable
CUSIP
No. 00973E102
|
|
13G
|
|
Page
5 of 5 Pages
|
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
December
22, 2017
|
|
(Date)
|
|
|
|
/s/
Konrad Ackermann
|
|
(Signature)
|
|
|
|
Konrad
Ackermann, Director
|
|
(Name/Title)
|
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2023 to Apr 2024